Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug-March 2024-www.financetom.com

Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug

Dec 23, 2024 5:51 AM

08:36 AM EST, 12/23/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday it dosed the first patients in a phase 1/2a clinical trial of ARO-INHBE, the company's investigational therapy to counter obesity.

The study will treat patients with ARO-INHBE as monotherapy in part 1 and in combination with tirzepatide in part 2.

The company also recently filed for regulatory clearance to launch a clinical trial of its second obesity candidate, ARO-ALK7.

Shares of the company were up more than 2.5% in Monday's premarket activity.

Previous page： Eastman Kodak Q4 Net Income, Revenue Decline Next page： Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Eastman Kodak Q4 Net Income, Revenue Decline

Mar 14, 2024

05:10 PM EDT, 03/14/2024 (MT Newswires) -- Eastman Kodak ( KODK ) reported Q4 net income late Thursday of $5 million, down from $7 million a year earlier. Revenue for the quarter ended Dec. 31 was $275 million, down from $305 million a year earlier. Capital IQ estimates weren't available. Price: 5, Change: +0.01, Percent Change: +0.2 ...

Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing

Mar 14, 2024

05:08 PM EDT, 03/14/2024 (MT Newswires) -- Phillip Frost, 10% Owner, Director, CEO & Chairman, on March 14, 2024, executed a purchase for 500,000 shares in Opko Health ( OPK ) for $444,300. Following the Form 4 filing with the SEC, Frost has control over a total of 243,664,353 shares of the company, with 3,068,951 shares held directly and 240,595,402...

Cipher Pharmaceuticals Q4 Profit Falls 61% on Charges

Mar 14, 2024

05:08 PM EDT, 03/14/2024 (MT Newswires) -- Cipher Pharmaceuticals ( CPHRF ) on Thursday said its fourth-quarter profit fell 61% on charges. The company said it earned US$7.7 million, or US$0.32 per share, in the period, down from a profit of US$19.7 million, or US$0.78 in the year-prior quarter. Cipher said the drop was largely attributable to the recognition of...

Brown & Brown Insider Sold Shares Worth $20,210,253, According to a Recent SEC Filing

Mar 14, 2024

05:09 PM EDT, 03/14/2024 (MT Newswires) -- Hyatt J Brown, 10% Owner, Director, Chairman, on March 12, 2024, sold 236,000 shares in Brown & Brown ( BRO ) for $20,210,253. Following the Form 4 filing with the SEC, Brown has control over a total of 39,558,518 shares of the company, with 39,558,518 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/79282/000120919124004845/xslF345X03/doc4.xml ...